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ABSTRACT
Introduction: Stroke has a high rate of long-
term disability and mortality and therefore has
a significant economic impact. The objective of
this study was to determine from a social
perspective, the cost–utility of magnetic
resonance imaging (MRI) compared to
computed tomography (CT) as the first
imaging test in acute ischemic stroke (AIS).
Methods: A cost–utility analysis of MRI
compared to CT as the first imaging test in AIS
was performed. Economic evaluation data were
obtained from a prospective study of patients
with AIS B12 h from onset in one Spanish
hospital. The measure of effectiveness was
quality-adjusted life-years (QALYs) calculated
from utilities of the modified Rankin Scale.
Both hospital and post-discharge expenses were
included in the costs. The incremental cost-
effectiveness ratio (ICER) was calculated and
sensitivity analysis was carried out. The costs
were expressed in Euros at the 2004 exchange
rate.
Results: A total of 130 patients were analyzed.
The first imaging test was CT in 87 patients and
MRI in 43 patients. Baseline variables were
similar in the two groups. The mean direct
cost was €5830.63 for the CT group and
€5692.95 for the MRI group (P = not
significant). The ICER was €11,868.97/QALY.
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The results were sensitive when the indirect
costs were included in the analysis.
Conclusion: Total direct costs and QALYs were
lower in the MRI group; however, this
difference was not statistically significant. MRI
was shown to be a cost-effective strategy for the
first imaging test in AIS in 22% of the iterations
according to the efficiency threshold in Spain.
Keywords: Acute ischemic stroke; Computed
tomography; Cost–utility analysis; Magnetic
resonance; Spain; Stroke
INTRODUCTION
According with Global Burden of Diseases,
Injuries, and Risk Factors Study [1], stroke was
the secondmost common cause of death and the
third most common cause of disability-adjusted
life-years worldwide in 2010 [2]. Patients who
survive a stroke have a higher risk of another
stroke, ischemic heart disease, or dementia [3].
Stroke has a considerable economic impact
during hospitalization and following discharge
[4–11]. Major advances in acute stroke care
include the creation of dedicated stroke units
[12], thrombolytic therapy [13, 14], and new
diagnostic techniques, especially imaging
techniques. Recent research into drugs for
treating stroke is based on the identification of
the diffusion–perfusion mismatch in magnetic
resonance imaging (MRI).
Despite technological advances in
neuroimaging, computed tomography (CT)
remains the examination of choice in patients
with acute stroke [15]. MRI is more sensitive and
more specific than CT in early detection of
acute ischemic stroke (AIS) [16–18]; moreover,
the variability in the interpretation of results is
lower in MRI [16]. MRI in patients with acute
stroke allows for a rapid diagnostic evaluation
and provides necessary and relevant
information [19]. Furthermore, MRI
techniques are as effective as CT for ruling out
or defining the magnitude of hemorrhage [20–
22]. Thrombolysis based on MRI C3 h after
stroke onset is safer and potentially more
effective than thrombolysis based on CT
within 3 h in patients with acute stroke [23,
24]. However, MRI is more expensive and less
widely available than CT.
The current study aimed to determine, from
a societal perspective, the cost–utility of MRI
compared with CT as the first imaging test in
patients with AIS.
METHODS
A cost–utility analysis from societal perspective
was developed. The study was conducted in
patients with AIS at a referral hospital for stroke
in Girona, Spain. The Hospital Doctor Josep
Trueta’s (Girona, Spain) ethics committee
approved the study. All procedures followed
were in accordance with the ethical standards of
the responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
from all patients for being included in the
study.
Data for the economic evaluation were
obtained from an ad hoc prospective
observational study that included patients
with AIS who presented or were referred to the
hospital between December 1, 2003 and March
9, 2005. The inclusion criteria were:
age C18 years, stroke less than 12 h from
onset, admission to the hospital’s stroke unit,
and informed consent of the patient or relative.
A 90-day time horizon was considered for
outcomes according to the hospital’s stroke
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management protocol. Because the time
horizon was less than a year, future
discounting was not required.
Alternatives Evaluated
The alternatives evaluated were cranial CT and
cranial MRI (diffusion, perfusion MRI, and
angiography). These alternatives were selected
because CT was the most used in the study
period and MRI was the technology that was to
be evaluated, for the advantages in sensitivity,
specificity [16], vascular occlusion, and
mismatch area.
Patientswere assigned toundergoCTorMRI as
the initial imaging technique in function of the
availability of scanners at the time of emergency
room admittance: patients admitted between
8 a.m. and 8 p.m. on weekdays (except holidays)
underwent MRI as the initial imaging test,
whereas patients admitted between 8 p.m. and
8 a.m. on weekdays or at any time on weekends
and holidays underwent CT.
Hospital and Post-Discharge Costs
According to the perspective of the study, both
direct health costs and other patient’s costs
were included. The expenditure for the
following resources used in the hospital was
quantified for each patient: Cranial CT, cranial
MRI, others diagnostic tests, physiotherapy,
pharmacological treatment, and hospital stay.
In addition, a questionnaire was used to obtain
information from patients about the post-
discharge resources used in the first 90 days
after onset, for example, institutionalization,
rehabilitation, home adaptations, caregivers,
and pharmacological treatment. All
expenditures were expressed in Euros (2004).
The information source for the costs is shown in
the results.
Effectiveness
The measure of effectiveness was quality-
adjusted life-years (QALYs). QALYs were
estimated from utility values obtained from
the modified Rankin Scale (mRS) and the time
(in years) that the patient remained in that
health state (mRS). The mRS is a tool widely
used to assess primary or secondary outcomes in
multicenter studies of stroke. The scale is
validated in several languages, including
Spanish [25]. This scale has been used in other
studies, including a clinical trial for a
neuroprotective stroke agent, and reflects
changes in the health status of patients [26].
The mRS was determined by a structured
interview [27] before stroke, at hospital
discharge, and 90 days after stroke. The
investigator who assessed the mRS was trained
and certified in the use of the mRS and was
blinded to the diagnostic imaging test
performed. A favorable clinical outcome was
defined as an mRS score C2.
For each value of the mRS, a utility value
obtained from previous studies [28, 29] was
assigned. These utilities were used because they
were obtained from the Spanish general
population through different methods of
measurement preferences. Each health state
(mRS) was associated with a utility value [28].
As in that study [28], no utility value was
assigned to patients with an mRS score of zero,
it was decided to give a utility value of 0.90 that
was obtained from a cost–utility analysis of
recombinant tissue plasminogen activator (rt-
PA) in patients with stroke [29]. Table 1 shows
the utility value used in the current study for
each mRS value.
The times considered for the calculation of
QALYs were: Time 1 (in years) = length of
hospital stay (LOS)/365 stay (from the stroke
to discharge); and time 2 (in years) = (90 days-
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LOS)/365 (from discharge until 90 days after
stroke).
Incremental Cost-Effectiveness Ratio
The total costs (hospital and post-discharge
costs) for each study group were calculated.
The incremental cost-effectiveness ratio (ICER)
was calculated as follows: (Cost MRI-Cost CT)/
(QALY MRI-QALY CT).
Clinical Data Collection
In addition to the data for economic evaluation,
the following variables were recorded: Sex, age,
cardiovascular risk factors, prior treatment, date
and hour of symptoms onset, and prior
functional dependence. Stroke severity was
determined daily by the National Institutes of
Health Stroke Scale (NIHSS).
Analysis
Data were analyzed for associations between
categorical variables with the Chi-square test.
The comparison of medians was done with the
non-parametric Mann–Whitney U test. The
comparison of means was done with Student’s
t test. Statistical significance was set at 0.05.
One-way and multi-way sensitivity analyses
were performed. In the one-way analysis, utility
parameters (obtained by visual analog scale
[VAS]), indirect costs, including lost
productivity from days off work (obtained in
the interview with the patient or caregiver), and
adjusted QALY (assuming the patient’s initial
mRS remained unchanged) were considered.
The multi-way sensitivity analysis was
performed using non-parametric bootstrapping
[30]; a total of 1000 bootstrap samples were
obtained.
Data were analyzed with SPSS (version
15.0., SPSS Inc., Chicago, IL, USA).
RESULTS
Of 472 consecutive patients with stroke, 130
fulfilled the inclusion criteria. Of these, 87
patients underwent CT as the first imaging test
and 43 patients underwent MRI. A total of 117
patients were alive 90 days after stroke and 3
patients were lost to follow-up. Baseline values
did not differ between the two groups: 60%
were male, most were retired, and 85% had an
mRS score of 0 before stroke (Table 2).
In both groups, hospital stay accounted for
approximately 80% of hospital costs, and
institutionalization accounted for nearly 45%
of the post-discharge costs until 90 days after
stroke (Table 3). On the other hand, no
significant differences between the two groups
were found in mRS (Table 4).
Table 5 shows the results of the ICER analysis.
The use of MRI was observed to be a less
expensive alternative, but resulted in less QALY
than CT for the diagnosis of AIS. In the one-way
sensitivity analyses, the ICER increased with all










The DG and VAS are methods of estimating utilities.
Source: Pinto-Prades and Abella´n-Perpin˜a´n [28]
DG double gamble, mRS modiﬁed Rankin Scale, VAS
visual analog scale
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variables included, except with the adjusted
QALY (Table 6). In the ICER analysis performed
with the bootstrap, the simulated cases mainly
fall in quadrants III and IV (Fig. 1). This result is
confirmed in the acceptability curve of cost-
effectiveness, where it can be appreciated that







Mean (SD) 69 (11) 68 (13) 0.685
30–45 years 3.4% 7.0%
46–60 years 19.5% 16.3%
61–75 years 43.7% 51.2%
76–90 years 33.3% 25.6%
Sex, male 55.2% 69.8% 0.110





Receiving compensation 2.6% 2.8%
Risk factors
Hypertension 67.8% 60.5% 0.407
Atrial ﬁbrillation 20.7% 18.6% 0.780
AMI 8.0% 11.6% 0.507
Diabetes mellitus 23.0% 16.3% 0.375
Smoking 14.9% 18.6% 0.593
Prior stroke 17.2% 14.0% 0.632
mRS score prior to stoke
0 90.8% 88.4% 0.906
1 5.7% 7.0%
2 3.5% 4.6%
NIHSS at admission, median (IQR) 8 (4–16) 7 (3–18) 0.825
Time from stroke onset to imaging, minutes, mean (SD) 262.15 (173.56) 256.36 (175.45) 0.860
AMI acute myocardial infarction, CT computed tomography, MRI magnetic resonance imaging, mRS modiﬁed Rankin
Scale, NIHSS National Institutes of Health Stroke Scale, SD standard deviation
a Information available only for patients, whose discharge destination was home, 72.4% and 74.4% for CT and MRI,
respectively
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22% of the iterations of the MRI result in a cost
per QALY of €30,000, regarded as the limit of
efficiency in Spain (Fig. 2).
DISCUSSION
The findings of the current study show that
clinical outcomes at discharge and 90 days
after stroke, as well as the total direct costs,
were similar for patients in the two groups.
Interestingly, although MRI examination
was nearly four times more expensive than
CT examination to assess AIS, the overall
direct hospital costs were not higher in the
group examined with MRI. These results are
in line with those reported by Beinfeld and
Gazelle [31], who found no increase in
hospital costs between 1996 and 2002
despite a substantial increase in the use of
CT and MRI.
The median LOS in the stroke unit was lower
in the MRI group which may be due to earlier
diagnosis and initiation of treatment, and
possibly attributable to greater confidence in
the information provided by MRI. In both
groups, the mean LOS was lower than
previously reported values (9.2–26 days) [6, 32,
33]; however, these studies included patients
with cerebral hemorrhage.
Total direct hospital costs did not differ
between groups, although the mean cost in
the MRI group was slightly lower due to the
shorter hospital stay in that group. As reported
in other studies [6, 7, 11, 34–36], hospital stay
was the largest single expenditure in the acute
phase, particularly when the patient was in the
stroke unit.
In line with another study in stroke patients
[10], only 24% of patients in the current study
were employed when the stroke occurred. Most
patients returned home after hospital discharge,
also in agreement with the results of other
studies [9, 10]. This data was reflected in
sensitivity analysis where when costs due to
Table 4 Modiﬁed Ranking Scale at discharge and 90 days
after stroke
Variable CT MRI P value
mRS at discharge n = 87 n = 43
Mean (SD) 3.4 (1.5) 3.4 (1.6) 0.980
Categorized mRS score
B2 26.4% 34.9% 0.891
3–5 71.3% 60.5% 0.424
Death 2.3% 4.7%
mRS at 90 days after
stroke
n = 85 n = 42 0.276
Mean (SD) 2.6 (1.8) 3.0 (2.0)
Categorized mRS score
B2 50.6% 42.9% 0.503
3–5 41.2% 42.9%
Death 8.2% 14.2%
CT computed tomography, MRI magnetic resonance
imaging, mRS modiﬁed Rankin Scale, SD standard
deviation
Table 5 Cost-effectiveness of MRI versus CT in patients with acute ischemic stroke






MRI 5692.95 -137.68 0.04070 -0.1160 11,868.97
CT computed tomography, ICER incremental cost-effectiveness ratio, MRI magnetic resonance imaging, QALY quality-
adjusted life-year
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lost productivity were included (days off work)
the ICER was higher.
More than half of the patients in the current
study needed a caregiver; 71% of the caregivers
were not paid, a proportion in line with the
results of a previous study [9], in which 74% of
the patients who required assistance were
attended by family members or friends. Thus,
informal care plays an important role in stroke.
Approximately, 26% of the caregivers in the
current study were family members who had to
leave their jobs to care for the patient.
In this study, the use of MRI rather than CT
as the initial diagnostic tool for assessing stroke
patients did not result in better outcome at
discharge or 90 days after stroke. However, no
changes were made in the treatment protocol
for patients undergoing MRI for the initial
assessment. Because rt-PA treatment in the
first 3 h is based on the absence of
hemorrhage or extensive infarct, this
information can be reliably obtained with a
simple CT study. There were no significant
differences between the two groups in the
distribution of patients treated with rt-PA.
However, a recent study [37] found that using
MRI-based penumbra to select patients for
intravenous rt-PA after routine CT in patients
with AIS increased costs, but was more cost-
effective.
No significant differences between the
groups in mRS was found. Likewise, no
significant differences in the parameters that
were calculated from mRS, such as utilities and
QALYs, were found. ICER in the simulations
varied widely due to the lack of significant
differences in the effectiveness of the two
techniques.
When a sensitivity analysis using utility
values obtained with the VAS was performed,
the variation in effectiveness between the two
groups remained minimal (it was even lower
than in the analyses of the baseline data), so the
ICER was higher. As is shown in the graph of the
cost-effectiveness plane (Fig. 1), a considerable
proportion of the results of this study were
located in the third quadrant, indicating that
MRI is less expensive, but also less effective in
terms of QALYs. Thus, MRI is not considered a
dominant alternative or a dominated
alternative. However, in a proportion of the
bootstrap results MRI would be located in
quadrant IV, meaning that it was less effective
and more costly than CT. Thus, MRI would be a
dominated alternative.
Discussing two systematic reviews of cost-
effectiveness of CT and MRI for some clinical













ICER incremental cost-effectiveness ratio, QALY quality-
adjusted life-year, VAS visual analog scale
a VAS was used as utility to calculate QALY
Fig. 1 Incremental cost-effectiveness (ICE) plane of MRI
versus CT in patients with acute ischemic stroke. Results
of probabilistic sensitivity analysis. Simulation cases of
patients in the CT and MRI group. CT computed
tomography, MRI magnetic resonance imaging, QALY
quality-adjusted life-year
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disorders (including stroke), Murtagh et al. [38]
highlight that diagnostic imaging technologies
can improve or expedite diagnosis of disease,
but do not necessarily change outcomes.
Indeed, many factors can affect a patient’s
outcome after imaging.
The current study has some limitations. The
small sample size may have made it difficult to
detect some significant differences; however, a
bootstrap analysis was performed to increase the
power of the study. The method for assigning
patients to the study groups depended on the
time of onset of stroke, and it cannot be ruled
out that this did not introduce a selection bias.
Nonetheless, at admission, the groups were
similar in neurological deficit, cardiovascular
risk factors, and prior disability.
The time horizon is important in economic
evaluations. Here 90 days was used; this follow-
up period is similar to other studies of the costs
and of managing stroke [8, 39, 40]. In this sense,
one study of the cost-effectiveness of
thrombolytic therapy with alteplase [41]
concluded that thrombolytic therapy based on
MRI is not cost-effective in the short term;
however, in the long term (at 3 years and
30 years) thrombolytic therapy based on MRI
was the dominant alternative compared to
conventional treatment.
Another important limitation is the cost. In
the current study, costs are presented in Euros at
the 2004 exchange rate. It was not considered
appropriate to update the costs to 2014 because
there were different aspects to consider other
than the consumer price index, such as the
structure of the market (supply, demand,
innovation, and economic crisis among
others). Nonetheless, the decision making of
those technologies is supported by the
sensitivity analysis.
The current results indicate that it is
economically and clinically feasible to perform
emergency MRI to diagnose AIS. These results
could be extrapolated to other settings where
diffusion-weighted imaging, perfusion MRI,
and/or MRI angiography are available, because
if those conditions are not fulfilled the
investment needed to purchase this
technology would have to be included in the
analysis. In addition to a suitable infrastructure,
coordinated teamwork among the neurology,
emergency, and radiology departments is
extremely important. Without the
interdisciplinary teamwork in stroke
management at the authors’ hospital, it would
have been impossible to carry out this study.
These results may help guide hospital
financial managers and clinicians. However, it
is important to emphasize that the decision of
which neuroimaging technique to apply must
always be made on an individual basis in
function of the patient’s age, symptoms, time
since onset of the event, and availability of the
imaging techniques, among other factors. More
studies on the cost-effectiveness of new imaging
studies will be needed when radiological
findings, such as brain hemodynamics, volume
of the penumbra, size of the infarction, and
Fig. 2 Acceptability curve of magnetic resonance imaging
versus computed tomography in patients with acute
ischemic stroke. QALY quality-adjusted life-year
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presence of vascular occlusion, are included in
the treatment protocols of AIS.
CONCLUSION
The three main findings obtained from this
study that can be considered when deciding
which imaging technique to use for the initial
assessment in AIS are: (1) Health outcomes are
equivalent whether CT or MRI is used, since
therapeutic decision making is not based on
neuroimaging results; (2) the direct costs related
to the use of CT or MRI are equivalent because
the higher post-discharge costs in the MRI
group is compensated by the lower direct cost
of hospitalization and the need for MRI in some
patients initially examined with CT; and (3) the
cost-effectiveness analysis performed with the
bootstrap method indicates that MRI was cost-
effective in a proportion of cases. Caution is
warranted in interpreting these results.
Although the cost information used was
from 2004, and considering the modifications
over time that this implies, it is important to
bear in mind that the conclusions described will
stay the same. Additionally, this study will
allow the authors to verify their conclusions
with a new prospective multicenter study on
the management of MRI on patients with AIS in
the future.
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